Drugs / BR-TD-1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04618939 | Oct 2016 → Apr 2017 | diphtheria, tetanus | Boryung Biopharma Co., Ltd. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR-TD-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04618939 ↗ |
| Modality | Vaccine | “The purpose of this study is to evaluate immunogenicity by measuring the seroprotection rate against diphtheria and tetanus at 28 days after vaccination with BR-TD-1001 and Td-pur-inj.” NCT04618939 ↗ |